<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006171.pub4" GROUP_ID="PREG" ID="030905062417033635" MERGED_FROM="" MODIFIED="2015-10-19 11:56:40 +0100" MODIFIED_BY="Leanne Jones" REVIEW_NO="0280" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2015-10-19 11:56:40 +0100" MODIFIED_BY="Leanne Jones">
<TITLE>Prenatal education for congenital toxoplasmosis</TITLE>
<CONTACT MODIFIED="2015-10-19 11:56:40 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="602B558382E26AA2019829A92356A34E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Simona</FIRST_NAME><LAST_NAME>Di Mario</LAST_NAME><EMAIL_1>sdimario@regione.emilia-romagna.it</EMAIL_1><ADDRESS><DEPARTMENT>SaPeRiDoc, Primary health care, general medicine, planning and development of health services</DEPARTMENT><ORGANISATION>Regional health authority of Emilia-Romagna</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-10-19 11:56:40 +0100" MODIFIED_BY="Leanne Jones"><PERSON ID="602B558382E26AA2019829A92356A34E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Simona</FIRST_NAME><LAST_NAME>Di Mario</LAST_NAME><EMAIL_1>sdimario@regione.emilia-romagna.it</EMAIL_1><ADDRESS><DEPARTMENT>SaPeRiDoc, Primary health care, general medicine, planning and development of health services</DEPARTMENT><ORGANISATION>Regional health authority of Emilia-Romagna</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="15836" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vittorio</FIRST_NAME><LAST_NAME>Basevi</LAST_NAME><EMAIL_1>vbasevi@regione.emilia-romagna.it</EMAIL_1><ADDRESS><DEPARTMENT>SaPeRiDoc, Primary health care, general medicine, planning and development of health services</DEPARTMENT><ORGANISATION>Emilia-Romagna Regional health authority</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="6033C14682E26AA2019829A9C1DC0C6B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Carlo</FIRST_NAME><LAST_NAME>Gagliotti</LAST_NAME><EMAIL_1>cgagliotti@regione.emilia-romagna.it</EMAIL_1><ADDRESS><DEPARTMENT>Control of infectious disease Unit</DEPARTMENT><ORGANISATION>Regional agency for health and social care of Emilia-Romagna</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="602F45D082E26AA2019829A9C2BD5503" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniela</FIRST_NAME><LAST_NAME>Spettoli</LAST_NAME><EMAIL_1>d.spettoli@ausl.mo.it</EMAIL_1><ADDRESS><DEPARTMENT>SaPeRiDoc, Primary health care, general medicine, planning and development of health services</DEPARTMENT><ORGANISATION>Regional health authority of Emilia-Romagna</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="60318E0A82E26AA2019829A9C9ED4AE0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gianfranco</FIRST_NAME><LAST_NAME>Gori</LAST_NAME><EMAIL_1>gianfranco_gori@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>SaPeRiDoc, Primary health care, general medicine, planning and development of health services</DEPARTMENT><ORGANISATION>Regional health authority of Emilia-Romagna</ORGANISATION><CITY>Bologna</CITY><COUNTRY CODE="IT">Italy</COUNTRY></ADDRESS></PERSON><PERSON ID="11485" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Roberto</FIRST_NAME><LAST_NAME>D'Amico</LAST_NAME><POSITION>Assistant professor</POSITION><EMAIL_1>roberto.damico@unimore.it</EMAIL_1><MOBILE_PHONE>+39 3316213042</MOBILE_PHONE><ADDRESS><DEPARTMENT>Italian Cochrane Centre, Department of Diagnostic, Clinical and Public Health Medicine</DEPARTMENT><ORGANISATION>University of Modena and Reggio Emilia</ORGANISATION><ADDRESS_1>Via del Pozzo 71</ADDRESS_1><CITY>Modena</CITY><ZIP>41124</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 059 4223865</PHONE_1><FAX_1>+39 059 4223235</FAX_1></ADDRESS></PERSON><PERSON ID="60353C5D82E26AA2019829A9C80577D1" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nicola</FIRST_NAME><LAST_NAME>Magrini</LAST_NAME><POSITION>Secretary</POSITION><EMAIL_1>magrinin@who.int</EMAIL_1><ADDRESS><DEPARTMENT>Policy, Access and Use (PAU), Department of Essential Medicines and Health Products</DEPARTMENT><ORGANISATION>World Health Organisation</ORGANISATION><ADDRESS_1>Avenue Appia 20</ADDRESS_1><CITY>Geneva</CITY><ZIP>1211 GENEVA 27</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+ 41 22 791 21 11</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-06-11 23:57:39 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="31" MONTH="5" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="5" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-06-11 23:56:14 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-11 23:56:14 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Search updated and no new trial reports identified. 'Summary of findings' table incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-06-11 23:56:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="5" YEAR="2015"/>
<DESCRIPTION>
<P>Review updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-14 15:14:52 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-01-14 15:14:52 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>This review has been updated. The addition of one more included study has not changed the results and conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-14 15:14:49 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Search updated. No new studies identified.</P>
<P>One study (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>), previously classified as pending has been included. This review now contains two included studies (involving a total of 5455 women).</P>
<P>The methods have been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-03-28 09:43:20 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-05-25 12:02:28 +0100" MODIFIED_BY="Sonja L Henderson">
<INTERNAL_SOURCES MODIFIED="2012-11-02 09:25:51 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-11-02 09:25:51 +0000" MODIFIED_BY="[Empty name]">
<NAME>SaPeRiDoc, Direzione generale sanità e politiche sociali, Regione Emilia-Romagna, Bologna</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2015-05-25 12:02:28 +0100" MODIFIED_BY="Sonja L Henderson">
<SOURCE MODIFIED="2015-05-25 12:02:28 +0100" MODIFIED_BY="Sonja L Henderson">
<NAME>UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-19 11:42:36 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-10-19 11:42:36 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-02-21 09:56:04 +0000" MODIFIED_BY="Sonja Henderson">Prenatal education for congenital toxoplasmosis</TITLE>
<SUMMARY_BODY MODIFIED="2015-10-19 11:42:36 +0100" MODIFIED_BY="[Empty name]">
<P>Toxoplasmosis infection is caused by a parasite, <I>Toxoplasma gondii.</I> Eating or handling raw or insufficiently-cooked meat, not washing hands thoroughly after gardening, handling contaminated soil or water, or contact with cats' faeces can cause infection. Usually it is asymptomatic and self-limiting. Primary prevention involves educating the general public, filtering water and improving farm hygiene to reduce animal infection.</P>
<P>If pregnant women have not previously been exposed to the parasite and develop antibodies while pregnant, the infection can be transmitted from the mother to the fetus (congenital toxoplasmosis). This is rare but potentially has serious consequences such as malformation, mental retardation, deafness and blindness of the infected infant, intrauterine death or stillbirth. The probability of infection is greater during the third trimester but the risk of the fetus developing major clinical signs is greater early in pregnancy. Pregnant women are often unaware of risk factors for congenital toxoplasmosis. Offering prenatal education could mean that women adopt simple behavioral measures to avoid toxoplasmosis.</P>
<P>This review included two randomized controlled trials (involving 5455 women). Data could not be combined because each trial measured effectiveness in different ways. One study was from Canada and involved 432 women randomly assigned to a 10-minute presentation during a prenatal class about toxoplasmosis prevention or to a usual prenatal class. Losses to follow-up were high and 285 completed the post-test questionnaire in the third trimester. Only 5% of the intervention women recalled having obtained information on toxoplasmosis prevention during prenatal classes. However, the authors concluded that prenatal education can effectively change pregnant women's behavior as it increased pet, personal and food hygiene. The other trial conducted in France involved 5023 pregnant women with no evidence of toxoplasmosis infection (seronegative) who were randomly assigned to receive a brochure and an audiotape containing information for toxoplasmosis prevention, or to a usual prenatal class. Losses to follow-up were high and 2790 completed both pre-test and post-test questionnaire on behavior (44.5% loss to follow-up), whereas 3949 women were tested for blood antibodies (22.4% loss to follow-up). Women's behavior did not change after the intervention. Similarly, the seroconversion rate did not differ between groups (13 out of 2591 women seroconverted in the intervention and four out of 1358 in the control group).</P>
<P>Both trials were judged as having low methodological quality as assessed by the GRADE approach. This limits our confidence in the results. Evidence supporting prenatal education to prevent congenital toxoplasmosis is therefore limited.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-23 14:21:20 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-07 11:26:10 +0000" MODIFIED_BY="[Empty name]">
<P>Congenital toxoplasmosis is considered a rare but potentially severe infection. Prenatal education about congenital toxoplasmosis could be the most efficient and least harmful intervention, yet its effectiveness is uncertain.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of prenatal education for preventing congenital toxoplasmosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-11 23:57:52 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2015), and reference lists of relevant papers, reviews and websites.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-07-28 13:47:23 +0100" MODIFIED_BY="Heather Maxwell">
<P>Randomized and quasi-randomized controlled trials of all types of prenatal education on toxoplasmosis infection during pregnancy. Cluster-randomized trials were eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-14 15:15:30 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-23 14:21:20 +0100" MODIFIED_BY="[Empty name]">
<P>Two cluster-randomized controlled trials (RCTs) (involving a total of 5455 women) met the inclusion criteria. The two included trials measured the effectiveness of the intervention in different ways, which meant that meta-analysis of the results was not possible. The overall quality of the two studies, as assessed using the GRADE approach, was low, with high risk of detection and attrition bias in both included trials.</P>
<P>One trial (432 women enrolled) conducted in Canada was judged of low methodological quality. This trial did not report on any of the review's pre-specified primary outcomes and the secondary outcomes reported results only as P values. Moreover, losses to follow-up were high (34%, 147 out of 432 women initially enrolled). The authors concluded that prenatal education can effectively change pregnant women's behavior as it increased pet, personal and food hygiene. The second trial conducted in France was also judged of low methodological quality. Losses to follow-up were also high (44.5%, 2233 out of 5023 women initially enrolled) and differential (40% in the intervention group and 52% in the control group). The authors concluded that prenatal education for congenital toxoplasmoses has a significant effect on improving women's knowledge, whereas it has no effect on changing women's behavior. In this trial 17/3949 pregnant women seroconverted for toxoplasmosis: 13/2591 (0.5%) in the intervention group and 4/1358 (0.3%) in the control group. The rate of seroconversion detected during the study did not differ between groups (risk ratio (RR) 1.70, 95% confidence interval (CI) 0.56 to 5.21; participants = 3949; studies = one, <I>low quality evidence</I>). The number of events was too small to reach conclusions about the effect of prenatal education on seroconversion rate during pregnancy.</P>
<P>No other randomized trials on the effect of prenatal education on congenital toxoplasmosis rate, or toxoplasmosis seroconversion rate during pregnancy were detected.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-28 13:42:05 +0100" MODIFIED_BY="Heather Maxwell">
<P>Even though primary prevention of congenital toxoplasmosis is considered a desirable intervention, given the lack of related risks compared to secondary and tertiary prevention, its effectiveness has not been adequately evaluated. There is very little evidence from RCTs that prenatal education is effective in reducing congenital toxoplasmosis even though evidence from observational studies suggests it is. Given the lack of good evidence supporting prenatal education for congenital toxoplasmosis prevention, further RCTs are needed to confirm any potential benefits and to further quantify the impact of different sets of educational intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-10-19 11:37:12 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-09-23 14:03:56 +0100" MODIFIED_BY="[Empty name]">
<P>Readers may wish to refer to the following Cochrane systematic review for further information about toxoplasmosis in pregnancy: '<I>Treatments for toxoplasmosis in pregnancy</I>' (<LINK REF="REF-Peyron-1999" TYPE="REFERENCE">Peyron 1999</LINK>).</P>
<CONDITION MODIFIED="2015-07-28 13:48:02 +0100" MODIFIED_BY="Heather Maxwell">
<P>Congenital toxoplasmosis is a rare (<LINK REF="REF-NSC-2001" TYPE="REFERENCE">NSC 2001</LINK>), but potentially severe parasitic infection that can lead to intrauterine death or stillbirth, malformation, mental retardation, deafness and blindness of the infected infant (<LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>). Incidence of congenital toxoplasmosis varies from one to 10 per 10,000 live children in Western countries (<LINK REF="REF-Gilbert-1999" TYPE="REFERENCE">Gilbert 1999</LINK>; <LINK REF="REF-Schmidt-2006" TYPE="REFERENCE">Schmidt 2006</LINK>; <LINK REF="REF-Signorell-2006" TYPE="REFERENCE">Signorell 2006</LINK>), to 16 per 1000 in Brazil (<LINK REF="REF-Reis-1999" TYPE="REFERENCE">Reis 1999</LINK>). The infection is caused by <I>Toxoplasma gondii</I> (<I>T. gondii</I>). <I>T. gondii</I> is one of the most common infectious pathogenic animal parasites of man, belonging to the phylum apicomplexa group (<LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>). Other members of this phylum include known human pathogens such as <I>Plasmodium</I> (malaria) and <I>Cryptosporidium</I>. It is acquired by ingesting oocysts excreted by cats, contaminated soil or water, or by eating the undercooked meat of infected animals, which contain tissue cysts (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>; <LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>). Most cases of toxoplasmosis infection are asymptomatic and self-limited except for congenital infection and immunocompromised patients (<LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>); hence many cases remain undiagnosed. The incubation period of acquired infection is estimated to be within the range of four to 21 days (seven days on average) (<LINK REF="REF-Rorman-2006" TYPE="REFERENCE">Rorman 2006</LINK>). Serological surveys demonstrate that worldwide exposure to <I>T. gondii</I> is high (30% in USA and 50% to 80% in Europe) (<LINK REF="REF-Rorman-2006" TYPE="REFERENCE">Rorman 2006</LINK>). The susceptibility of pregnant women (that is the rate of seronegative pregnant women) to toxoplasmosis varies between countries. It is up to 90% in northern Europe, where <I>T. gondii</I> is not so common (<LINK REF="REF-Allain-1998" TYPE="REFERENCE">Allain 1998</LINK>; <LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>). When infection does occur during pregnancy, <I>T. gondii</I> can be transmitted from the mother to the fetus (vertical transmission) and can lead to congenital toxoplasmosis. Multiple factors are associated with the occurrence of congenital toxoplasmosis infection, including route of transmission, climate, cultural behavior, eating habits and hygenic standards (<LINK REF="REF-Rorman-2006" TYPE="REFERENCE">Rorman 2006</LINK>). The probability of transmission of the parasite to the fetus varies according to the gestational age and the risk is greater during the third trimester (from 5% at 12 weeks to 80% just before delivery) (<LINK REF="REF-Dunn-1999" TYPE="REFERENCE">Dunn 1999</LINK>). Conversely, the severity of the condition, that is the risk of the fetus developing major clinical signs, decreases with increasing gestational age (from 60% at 12 weeks to 5% just before delivery) (<LINK REF="REF-Dunn-1999" TYPE="REFERENCE">Dunn 1999</LINK>). Clinical features include hydrocephalus (excessive accumulation of cerebrospinal fluid within the cranium), microcephaly (abnormal smallness of the head, usually associated with mental retardation), deafness, cerebral calcifications, seizures and psychomotor retardation. Signs of a systemic infection may also be present at birth, including fever, rash, and enlargement of liver and spleen. Fetal infection can cause inflammatory lesions of the retina and choroids that can lead to visual impairment. Moreover, it can cause lesions of the brain leading to mental damage; more rarely, the infection can cause the death of the fetus or the newborn (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>; <LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>; <LINK REF="REF-NSC-2001" TYPE="REFERENCE">NSC 2001</LINK>). Severe damage in infancy occurs in 5% of congenital toxoplasmosis cases, while intracranial or ocular lesions are observed in 20% to 30% of cases by three years of age (<LINK REF="REF-Gilbert-2001" TYPE="REFERENCE">Gilbert 2001</LINK>).</P>
<P>Although there is no consensus on the most appropriate screening or treatment for congenital toxoplasmosis, three possible approaches have been proposed: prenatal screening, neonatal screening and primary prevention (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>). This systematic review will focus on primary prevention through prenatal education of pregnant women. Other possibilities are discussed below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Prenatal screening</HEADING>
<P>Prenatal screening (secondary prevention) is offered in some European countries, for example, France, Switzerland, Germany, Austria and Italy where the incidence of <I>T. gondii</I> maternal infection is more frequent, and is based on the timely detection of the mother's infection by a serum test for toxoplasma Immunoglobulin G (IgG) and Immunoglobulin M (IgM) (<LINK REF="REF-NSC-2001" TYPE="REFERENCE">NSC 2001</LINK>). If the first prenatal test shows signs of recent infection or a seroconversion is detected during pregnancy, a confirmatory test is required before starting treatment with spiramycin or pyrimethamine-sulfadoxine, or both (<LINK REF="REF-Foulon-1999a" TYPE="REFERENCE">Foulon 1999a</LINK>; <LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>; <LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>). Diagnosis of fetal infection is performed by amniocentesis, which is known to be associated with a 1% risk of miscarriage (<LINK REF="REF-Alfirevic-2003" TYPE="REFERENCE">Alfirevic 2003</LINK>), and testing of the amniotic fluid for the detection of the parasite or of toxoplasma DNA by polymerase chain reaction (PCR) technique. Congenital toxoplasmosis can also be diagnosed by cordocentesis, that consists of drawing fetal blood from the umbilical cord, and the detection of the parasite or specific immunoglobulin (IgM and IgA) in the fetal blood, but the risk of complications due to the procedure is higher (<LINK REF="REF-Bader-1997" TYPE="REFERENCE">Bader 1997</LINK>; <LINK REF="REF-Foulon-1999b" TYPE="REFERENCE">Foulon 1999b</LINK>; <LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>). If fetal infection is confirmed, the parents can decide either to terminate the pregnancy or to opt for drug treatment. Prenatal screening, although advocated by some as essential for reducing congenital toxoplasmosis (<LINK REF="REF-Boyer-2005" TYPE="REFERENCE">Boyer 2005</LINK>), has several limitations: false-positive toxoplasma IgM results are common, false-positive toxoplasma IgG are less common but also possible (<LINK REF="REF-Liesenfeld-1997" TYPE="REFERENCE">Liesenfeld 1997</LINK>; <LINK REF="REF-Montoya-2004" TYPE="REFERENCE">Montoya 2004</LINK>); moreover, the rate of false-positive test results can increase, notably in settings where local prevalence of the infection is lower; there can be organizational problems or problems of acceptability due to the need to repeat the serum test every four to six weeks in seronegative women (<LINK REF="REF-Bader-1997" TYPE="REFERENCE">Bader 1997</LINK>); there is no evidence that antenatal treatment is effective in reducing transmission to the fetus nor in improving neonatal outcomes or reducing functional impairment in later childhood (<LINK REF="REF-Gilbert-2003" TYPE="REFERENCE">Gilbert 2003</LINK>; <LINK REF="REF-Peyron-1999" TYPE="REFERENCE">Peyron 1999</LINK>; <LINK REF="REF-SYROCOT-2007" TYPE="REFERENCE">SYROCOT 2007</LINK>); there are problems concerning the accuracy of the diagnostic test for fetal infection, particularly the lack of a standardized technique for PCR (<LINK REF="REF-Chabbert-2004" TYPE="REFERENCE">Chabbert 2004</LINK>; <LINK REF="REF-Foulon-1999b" TYPE="REFERENCE">Foulon 1999b</LINK>; <LINK REF="REF-Thalib-2005" TYPE="REFERENCE">Thalib 2005</LINK>). Finally, this strategy causes additional fetal losses of healthy fetuses due to amniocentesis and to elective terminations of pregnancy. It has been estimated that the number of additional losses necessary to prevent one additional case of toxoplasmosis can be as high as 18.5 in cases of universal screening in a setting with a low incidence of <I>T. gondii</I> maternal infection, such as the USA (<LINK REF="REF-Bader-1997" TYPE="REFERENCE">Bader 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neonatal screening</HEADING>
<P>Neonatal screening (tertiary prevention), adopted in Poland, Denmark and some areas of the USA (<LINK REF="REF-NSC-2001" TYPE="REFERENCE">NSC 2001</LINK>), consists of the diagnosis of newborn infection through detection of toxoplasma specific IgM on Guthrie card blood spots. In fact, up to 90% of infected infants are asymptomatic at birth and will show clinical symptoms only in later life (<LINK REF="REF-Gilbert-2001" TYPE="REFERENCE">Gilbert 2001</LINK>; <LINK REF="REF-Wilson-1980" TYPE="REFERENCE">Wilson 1980</LINK>). Current guidelines suggest that infected infants should receive treatment with pyrimethamine and sulfadiazine for up to one year, regardless of symptoms (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>). Even if this strategy is technically feasible and less costly than prenatal screening, it has been proven to have a low sensitivity, even when the test is performed on serum samples, which are more valid than the test on filter paper blood samples currently used: neonatal screening is not able to detect almost half of all infected infants (<LINK REF="REF-Gilbert-2007" TYPE="REFERENCE">Gilbert 2007</LINK>). Moreover, there is no evidence that treating the infected children has any effect (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>; <LINK REF="REF-Lebech-1999" TYPE="REFERENCE">Lebech 1999</LINK>). Finally, this approach is ineffective on irreversible damage already present at birth. Considering such limitations, neonatal screening should be adopted only in places where other options are not available; the implications of such a policy should be fully discussed with the parents of the tested newborn.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Primary prevention</HEADING>
<P>Primary prevention can involve the whole population by educating the general public and filtering water, and veterinary public health interventions (such as labeling to indicate toxoplasma-free meat and improved farm hygiene to reduce animal infection). This will reduce the protozoan circulation and could be an option but up to now there is not enough research to determine the feasibility and efficacy of this approach (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>; <LINK REF="REF-NSC-2001" TYPE="REFERENCE">NSC 2001</LINK>). Another possibility is primary prevention based on prenatal education of pregnant women or women of reproductive age to avoid toxoplasmosis in pregnancy (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-09-23 14:03:56 +0100" MODIFIED_BY="[Empty name]">
<P>This review evaluates the effectiveness of prenatal education for reducing the risk to develop toxoplasmosis infection during pregnancy. Various types of prenatal education exist and can be proposed in different settings, either as a stand alone intervention or as a component of a multifaceted intervention program and they are all assessed in this review. Prenatal educational interventions could include: antenatal classes provided to pregnant women, distribution of leaflets to pregnant women or to women of reproductive age, irrespective of their pregnant status, one-to-one or group counseling from different professionals (nurses, midwives, obstetricians and gynecologists, social workers, counselors, teachers, trained lay people, etc), educational intervention in schools, mass-media campaign and others.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-07-28 13:48:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>Primary prevention based on prenatal education, if proven to be effective, could be a good strategy to reduce congenital toxoplasmosis, since it will not involve any of the problems linked to secondary and tertiary prevention strategies. In fact, sources and risk factors for contracting toxoplasmosis are well known (<LINK REF="REF-Cook-2000" TYPE="REFERENCE">Cook 2000</LINK>), and can be avoided by adopting simple behavioral measures such as not eating raw or insufficiently cooked meat, washing hands thoroughly after handling raw meat and after gardening, avoiding contact with cats' faeces (directly or indirectly through the soil, or possibly contaminated raw vegetables or fruits) (<LINK REF="REF-Cook-2000" TYPE="REFERENCE">Cook 2000</LINK>; <LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>). Nevertheless, pregnant women are often unaware of risk factors for congenital toxoplasmosis (<LINK REF="REF-Ferguson-2011" TYPE="REFERENCE">Ferguson 2011</LINK>). If adequately informed, women can be more prone to change their own behavior during pregnancy than during any other period of their life; for this reason several intervention to promote healthy behavior are implemented during pregnancy (see other Cochrane systematic review on pregnancy and education <LINK REF="REF-Chamberlain-2013" TYPE="REFERENCE">Chamberlain 2013</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-07-28 13:48:29 +0100" MODIFIED_BY="Heather Maxwell">
<P>When this systematic review was first published in 2009, we aimed to synthesize available evidence on effective intervention to reduce congenital toxoplasmosis, a rare but potentially severe condition for which effective treatment is still lacking. Primary prevention was theoretically considered to be, and still is, the most valuable and safe intervention to reduce the incidence and prevalence of this congenital infection. Unfortunately, evidence of its effectiveness resulted to be scanty and studies poorly conducted or not adequately reported. A further update of the review, although permitted to add one more study to the list of included studies (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>) did not change the conclusion: prenatal education seem to be a promising intervention to reduce congenital toxoplasmosis but strong evidence is lacking. This review calls for further research on this relevant issue that is very likely to have an important impact on our confidence in the estimate of effect and is likely to change our conclusions; moreover, the systematic review provides methodological hints for producing valuable evidence that matter for policy makers, health professionals, and women.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-11-07 12:03:04 +0000" MODIFIED_BY="[Empty name]">
<P>The primary objectives of this review were to assess the efficacy of prenatal education to reduce the rate of:</P>
<OL>
<LI>new cases of congenital toxoplasmosis;</LI>
<LI>toxoplasmosis seroconversion during pregnancy.</LI>
</OL>
<P>Secondary objectives were to assess the efficacy of prenatal education to increase the rate of:</P>
<OL>
<LI>pregnant women's knowledge of risk factors for acquiring toxoplasmosis infection;</LI>
<LI>pregnant women's awareness of the importance of avoiding toxoplasmosis infection during pregnancy;</LI>
<LI>pregnant women's behavior with respect to avoidance of risk factors for toxoplasmosis infection during pregnancy.</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-23 14:10:39 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-07-28 13:48:52 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2013-01-11 16:05:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Randomized and quasi-randomized controlled trials evaluating any kind of prenatal educational intervention dealing with toxoplasmosis infection in pregnancy, and how to avoid it, were assessed for inclusion. Studies where the control group included an alternative intervention or no intervention were also considered for inclusion. Studies where the unit of randomization was a group of women (cluster-randomization) were assessed for inclusion and analyzed as a separate group. Interventions, exclusively focused on toxoplasmosis or interventions not exclusively focused on toxoplasmosis infection but where toxoplasmosis was included among a series of different topics, were also eligible for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-07-28 13:48:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Trials of women of reproductive age, irrespective of their pregnant status were included. Since a screening policy for toxoplasmosis infection is not universally adopted, studies including women, irrespective of their toxoplasmosis seropositive status were included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-07-28 13:48:52 +0100" MODIFIED_BY="Heather Maxwell">
<P>Any kind of prenatal education on toxoplasmosis infection during pregnancy. Prenatal educational interventions could include: antenatal classes provided to pregnant women, distribution of leaflets to pregnant women or to women of reproductive age, irrespective of their pregnant status, one-to-one or group counseling from different professionals (nurses, midwives, obstetricians and gynecologists, social workers, counselors, teachers, trained lay people, etc), educational intervention in schools, mass-media campaign and others.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-28 12:40:38 +0100" MODIFIED_BY="Heather Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-07-28 12:40:38 +0100" MODIFIED_BY="Heather Maxwell">
<OL>
<LI>Rate of congenital toxoplasmosis, defined by persistence of specific IgG antibodies beyond 11 months of age (<LINK REF="REF-Lebech-1996" TYPE="REFERENCE">Lebech 1996</LINK>).</LI>
<LI>Rate of toxoplasmosis seroconversion in pregnant women, defined by:</LI>
<OL>
<LI>an increase in specific IgG from paired sera in pregnant woman previously seronegative;</LI>
<LI>a rising IgG titre, low IgG avidity, IgA antibodies, or a combination of these in pregnant women who were IgG and IgM positive at their first prenatal test (<LINK REF="REF-Gilbert-2002" TYPE="REFERENCE">Gilbert 2002</LINK>).</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-05-18 16:35:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Pregnant women's knowledge of risk factors for acquiring toxoplasmosis infection as objectively measured (quantitative score) through specific questionnaire.</LI>
<LI>Pregnant women's awareness of the importance of avoiding toxoplasmosis infection during pregnancy as objectively measured (quantitative score) through specific questionnaire.</LI>
<LI>Pregnant women's behavior with respect to the avoidance of risk factors for toxoplasmosis infection during pregnancy as objectively measured (quantitative score) through specific questionnaire.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-06-11 23:42:06 +0100" MODIFIED_BY="[Empty name]">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-06-11 23:42:06 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (31 May 2015).</P>
<P>The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from:</P>
<OL>
<LI>monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE (Ovid);</LI>
<LI>weekly searches of Embase (Ovid);</LI>
<LI>monthly searches of CINAHL (EBSCO);</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE, Embase and CINAHL, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>.</P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.</P>
<P>For additional search strategy used in the previous version of this review (<LINK REF="REF-Di-Mario-2013" TYPE="REFERENCE">Di Mario 2013</LINK>), see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-16 23:24:47 +0000" MODIFIED_BY="Lynn Hampaon">
<P>We searched the reference lists of relevant papers, reviews and websites and contacted researchers working in the field for information on any relevant studies and for any additional published or unpublished studies.</P>
<P>We did not apply any language or date restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-23 14:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>For methods used in the previous version of this review, <I>see </I>
<LINK REF="REF-Di-Mario-2013" TYPE="REFERENCE">Di Mario 2013</LINK>.</P>
<P>For this update, no new reports were identified for assessment but we assessed the quality of evidence of the existing studies using the GRADE approach as outlined in the <A HREF="http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html">GRADE Handbook</A>. In order to assess the quality of the body of evidence relating to the following outcomes for the two comparisons: 'educational prenatal classes compared with usual prenatal classes and brochure and an audiotape compared with standard care'.</P>
<OL>
<LI>Rate of congenital toxoplasmosis.</LI>
<LI>Rate of toxoplasmosis seroconversion during pregnancy.</LI>
<LI>Pregnant women's knowledge of risk factors for acquiring toxoplasmosis infection.</LI>
<LI>Pregnant women's awareness of the importance of avoiding toxoplasmosis infection during pregnancy.</LI>
<LI>Pregnant women's behavior with respect to avoidance of risk factors for toxoplasmosis infection during pregnancy.</LI>
</OL>
<P>
<A HREF="http://www.gradepro.org/">GRADEpro</A> Guideline Development Tool was used to import data from Review Manager 5.3 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) in order to create &#8217;Summary of findings&#8217; tables. A summary of the intervention effect and a measure of quality for each of the above outcomes has been produced using the GRADE approach. The GRADE approach uses five considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious (or by two levels for very serious) limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias.</P>
<P>In future updates, if new reports are identified, we will use the methods described in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-07-28 13:50:25 +0100" MODIFIED_BY="Heather Maxwell">
<STUDY_DESCRIPTION MODIFIED="2015-07-28 13:49:22 +0100" MODIFIED_BY="Heather Maxwell">
<SEARCH_RESULTS MODIFIED="2015-06-11 23:55:00 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 925 reports that met the initial criteria for hard copy scrutiny. Five studies (nine reports) met the predetermined baseline criteria of assessing an educational intervention for toxoplasmosis prevention. Two studies (four reports) (involving 5455 women) have been included and three studies (five reports) have been excluded. <I>See</I> <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for diagram of the studies selection.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-07-28 13:49:22 +0100" MODIFIED_BY="Heather Maxwell">
<P>The first study compared two randomly allocated groups of women and was therefore included in the review (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>). The study was conducted in Ontario (Canada) and involved 432 pregnant women attending early prenatal classes in six centers. It was a cluster-randomized trial, that is, a trial where groups rather than individuals are randomized between or among comparator interventions; in this case, the units of randomization were the prenatal classes: 26 prenatal classes were randomly assigned to the intervention and 26 prenatal classes were assigned to control intervention (usual prenatal classes). A three-page handout was prepared along with a display poster and resource materials for teachers. Prenatal class instructors received one-hour basic training on toxoplasmosis prevention. The intervention group women were offered a 10-minute presentation focused on toxoplasmosis prevention during the first prenatal class. The contents of the intervention focused on cats, food, and personal hygiene. </P>
<P>The second study was a cluster-randomized trial conducted in France (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>). Women attending prenatal clinics in the area of Lyon were enrolled if they tested seronegative for toxoplasma antibodies. The unit of randomization was the city. Physicians in experimental cities provided women with a 20-page brochure containing four pages of information of toxoplasmosis plus an audiotape containing a conversation between a physician and his/her patient on issues relevant to pregnancy, including questions on toxoplasmosis. Women attending prenatal clinics in control cities received usual care. Knowledge and behavior were assessed through a questionnaire administered at baseline (usually during the third and fourth month of gestation) and at follow-up (after delivery). Only women who completed both questionnaires (2790 out of 5023) were included in the multivariate analysis to identify any association between the intervention and change in knowledge and behavior.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-05-14 11:53:38 +0100" MODIFIED_BY="[Empty name]">
<P>The remaining three studies were surveys conducted at the population level, without a control group (before and after studies) and were, therefore, excluded from the review as they were not randomized controlled trials. The details of the three studies are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. One study was from Belgium (<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>), one from Poland (<LINK REF="STD-Pawlowski-2001" TYPE="STUDY">Pawlowski 2001</LINK>), and one from Cuba (<LINK REF="STD-Mol_x00e9_-1992" TYPE="STUDY">Molé 1992</LINK>). In the Breugelmans study the intervention changed over time: the first intervention adopted (from 1983 to 1990) consisted of providing pregnant women with a list of recommended hygiene measures to avoid toxoplasma infection during pregnancy; thereafter (from 1991 to 2001) a leaflet containing information on congenital toxoplasmosis and how to avoid it was given to all pregnant women in addition to the list of recommendations and was assessed for effectiveness. Seroconvertion rate during pregnancy in the intervention period was compared with the seroconversion rate in the baseline period, when no intervention on toxoplasmosis prevention was in place (from 1979 to 1982) (<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>). The <LINK REF="STD-Pawlowski-2001" TYPE="STUDY">Pawlowski 2001</LINK> study used a multifaceted intervention including providing information to pregnant women, refresher training for health professionals, media campaigns, and the training of biology teachers in secondary schools, over six years and their effectiveness was assessed. It was impossible to obtain the full text of the study conducted in Cuba (<LINK REF="STD-Mol_x00e9_-1992" TYPE="STUDY">Molé 1992</LINK>): data retrieved from the abstract indicate that an educational intervention about how to avoid toxoplasmosis infection during pregnancy was delivered to seronegative pregnant women. All pregnant women were enrolled at their first prenatal visit. The number of women included in the surveys ranged from 1246 to 16,541. The <LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK> study contained data previously published in Foulon (<LINK REF="REF-Foulon-1988" TYPE="REFERENCE">Foulon 1988</LINK>; <LINK REF="REF-Foulon-1994" TYPE="REFERENCE">Foulon 1994</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-28 13:50:10 +0100" MODIFIED_BY="Heather Maxwell">
<P>We assessed the methodological quality of the included studies as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a summary of 'Risk of bias' assessments.</P>
<ALLOCATION MODIFIED="2015-07-28 13:49:43 +0100" MODIFIED_BY="Heather Maxwell">
<P>The Canadian trial (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>), was a cluster-randomized trial of low quality (<LINK REF="REF-Hahn-2005" TYPE="REFERENCE">Hahn 2005</LINK>; <LINK REF="REF-Puffer-2003" TYPE="REFERENCE">Puffer 2003</LINK>). The study reported that the groups were randomized but the randomizations method was not specified. Nevertheless, selection bias of the cluster is unlikely: the six centers provided almost all of the prenatal education available in that jurisdictional area; the study only lasted six months; an equal number of classes in each center received the experimental and the control intervention; authors stated that women in the experimental and control groups did not differ for demographic characteristics (even though a table reporting baseline data of the two groups was not provided), thus there is no strong reason to suspect that women attending prenatal classes in one period of time differ significantly from women attending prenatal classes in another period of time.</P>
<P>The second trial included (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>) was also a cluster-randomized trial of low quality: randomization method was not specified, therefore selection bias can not be excluded. The study, first used for a master thesis, was published in a short form as a poster, and thereafter included in a systematic review. In neither of the publications was the statistical plan of analysis described.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-06-29 14:12:08 +0100" MODIFIED_BY="Leanne V Jones">
<P>In both trials, performance bias was assessed as being at low risk: in both trials (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>; <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>), blinding of the women was reported, but blinding of the personnel was not possible, but this is unlikely to influence the outcome. Outcome measures referred to changes in behavior occurring between pre-test (usually in the first-second term of pregnancy in <LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK> and usually in the third and fourth month of pregnancy in <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>) and post-test questionnaire (in the third term of pregnancy in <LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK> and at delivery in <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>) in respect of hygiene measures to avoid toxoplasmosis. Since outcome measures were self-reported, detection bias can not be totally excluded in both of the included trials, even if women were blinded to the objective of the study.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-07-28 13:50:01 +0100" MODIFIED_BY="Heather Maxwell">
<P>In <LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>, losses to follow-up at the level of women participating in prenatal classes were 34% (432 women completed the pre-test questionnaire and 285 completed the post-test questionnaire): women in experimental group were more likely to be lost at follow-up than women in control group, therefore attrition bias can not be excluded (<LINK REF="REF-Puffer-2003" TYPE="REFERENCE">Puffer 2003</LINK>).</P>
<P>In <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK> overall losses to follow-up were 44.5%: women in the control group were more likely to be lost to follow-up (52% were lost) than women in intervention group (40% were lost), therefore also in the second included trial attrition bias can not be excluded (<LINK REF="REF-Puffer-2003" TYPE="REFERENCE">Puffer 2003</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-05-28 13:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>It was not clear in the two trials the extent of outcome data that were collected and therefore, unclear whether the outcomes were selectively reported. The primary outcomes were not reported in one study (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>), whereas it was reported in the more recent study (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-07-28 13:50:10 +0100" MODIFIED_BY="Heather Maxwell">
<P>Since the prenatal class instructors of the experimental and the control group in <LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK> were the same, it is not possible to exclude some contamination, even if such contaminations are usually not an issue in cluster trials (<LINK REF="REF-Torgerson-2001" TYPE="REFERENCE">Torgerson 2001</LINK>), and in any case, it would have acted in the sense of reducing the effect. The total sample, considering the unit of randomization, was low (26 prenatal classes in the intervention group and 26 prenatal classes in the control group). It is not clear from the paper if a statistical analysis was conducted to take into account the effect of intracluster correlation. The authors did not report raw data (number or proportion): only the P value for differences was reported. We also contacted the authors for the original data but we did not receive a reply. In <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>, the study method and statistical plan of analysis were not described in detail, therefore it is not possible to exclude other bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-28 13:50:25 +0100" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Comparison</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1) Educational prenatal classes compared with usual prenatal classes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The study did not report any of the review pre-specified outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>The first trial included in the review (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>), reported the following changes in behavior in the intervention group:</P>
<OL>
<LI>pet hygiene behavior: intervention classes reported to behave significantly better than the control class (P value reported &lt; 0.05);</LI>
<LI>food hygiene behavior: intervention classes reported to behave significantly better than the control class with respect to cooking roast beef (P value reported &lt; 0.05) and hamburgers (P value reported &lt; 0.01); remaining items were already good at the pre-test;</LI>
<LI>personal hygiene behavior intervention classes reported to behave significantly better than the control class only in the subgroup of women who had professional occupations (P value reported &lt; 0.05); remaining professional groups and other items considered were already good at the pre-test.</LI>
</OL>
<P>Only 5% of the women in the intervention group recall having obtained specific information on toxoplasmosis prevention during prenatal classes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2) Brochure and an audiotape compared with standard care</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<P>The second trial included in the review (<LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>) reported the following results:</P>
<OL>
<LI>seroconvertions for toxoplasmosis detected during the study did not differ between groups (risk ratio (RR) 1.70, 95% confidence interval (CI) 0.56 to 5.21; participants = 3949; one study) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>): there were 13 cases out of 2591 pregnant women (0.5%) in the intervention group and four cases out of 1358 pregnant women (0.3%) in the control group (P = 0.35).</LI>
<LI>The data above have not been adjusted for cluster design and so it is reasonable to assume the confidence intervals have been underestimated.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<P>These results were taken directly from the published report and odds ratios (OR) appear to have been adjusted for cluster design.</P>
<OL>
<LI>Prenatal education on congenital toxoplasmosis was not significantly associated to the outcome "no consumption of undercooked meat of any type" (multiple logistic regression, odds ratio (OR) 1.21; 95% CI 0.98 to 1.50).</LI>
<LI>prenatal education on congenital toxoplasmosis was not significantly associated to the outcome "handwashing after contact with transmission factor and before meals" (multiple logistic regression, OR 1.01; 95% CI 0.83 to 1.22).</LI>
<LI>baseline behaviors concerning toxoplasmosis, smoking and alcohol consumption were significantly associated with both the outcomes measured, after controlling for baseline knowledge.</LI>
</OL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-10-19 11:37:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-10-19 11:37:12 +0100" MODIFIED_BY="[Empty name]">
<P>Two cluster-randomized trials on primary prevention of congenital toxoplasmosis suggest that providing specific information during antenatal classes or prenatal visits about toxoplasmosis infection and how to avoid it can improve pregnant women's behavior (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>; <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>), but the overall quality of the trials was low.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-05-28 14:33:17 +0100" MODIFIED_BY="[Empty name]">
<P>Given the scarcity of evidence supporting the implementation of antenatal classes for congenital toxoplasmosis, and considering the current lack of evidence that alternative interventions such as screening and early treatment of infected pregnant women can reduce the risk of congenital toxoplasmosis, further research to quantify the impact of different educational interventions is needed.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-09-23 14:27:26 +0100" MODIFIED_BY="[Empty name]">
<P>All prespecified outcomes for two comparisons were assessed and assigned a quality rating using the GRADE methods. For the first comparison 'educational prenatal classes compared with usual prenatal classes', outcomes were either not reported or were reported in unusable format for 'Summary of findings' tables. Evidence from one trial for the comparison of brochure and an audiotape compared with standard care for the outcome of rate of toxoplasmosis seroconversion during pregnancy was assessed as of low quality. Evidence for the outcome of pregnant women's behavior with respect to avoidance of risk factors for no consumption of uncooked meat of any type was graded to be of moderate quality, while, for hand washing after contact with transmission factor and before meals was graded to be of low quality. Downgrading decisions were based in part on the high risk of bias of included trials and imprecise results.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-05-28 14:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>We have followed standard Cochrane methods to identify and evaluate the studies contributing to this review, and are confident that we have not missed any significant trials. We have sought missing or incomplete data, and have contacted authors where possible to clarify our interpretation of their work. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-07-28 13:50:51 +0100" MODIFIED_BY="Heather Maxwell">
<P>When the protocol for this systematic review was firstly published in 2006 no other systematic reviews on the effectiveness of prenatal education for toxoplasmosis congenital prevention were available. In 2008, a systematic review was conducted (<LINK REF="REF-Golloub-2008" TYPE="REFERENCE">Golloub 2008</LINK>) on this topic: six studies were described (<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>; <LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>; <LINK REF="REF-Foulon-2000" TYPE="REFERENCE">Foulon 2000</LINK>; <LINK REF="REF-Nguyen-2004" TYPE="REFERENCE">Nguyen 2004</LINK>; <LINK REF="STD-Pawlowski-2001" TYPE="STUDY">Pawlowski 2001</LINK>; <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>), two of which were randomized controlled trials (<LINK REF="STD-Carter-1989" TYPE="STUDY">Carter 1989</LINK>; <LINK REF="STD-Wallon-2006" TYPE="STUDY">Wallon 2006</LINK>), whereas the remaining trials were observational studies (<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>; <LINK REF="REF-Foulon-2000" TYPE="REFERENCE">Foulon 2000</LINK>; <LINK REF="REF-Nguyen-2004" TYPE="REFERENCE">Nguyen 2004</LINK>; <LINK REF="STD-Pawlowski-2001" TYPE="STUDY">Pawlowski 2001</LINK>). The authors did not provided a meta-analysis of the data due to inconsistent reporting of results; their conclusions are that there is some evidence that prenatal education can reduce toxoplasmosis infection during pregnancy but that more research on this topic is needed. In addition to the studies included in the <LINK REF="REF-Golloub-2008" TYPE="REFERENCE">Golloub 2008</LINK> review, one more observational study suggests that prenatal education might have a positive impact on reducing congenital toxoplasmosis (<LINK REF="STD-Mol_x00e9_-1992" TYPE="STUDY">Molé 1992</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-07-28 13:51:03 +0100" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-23 13:14:56 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence supporting prenatal education for preventing congenital toxoplasmosis is sparse and of low quality. Prenatal education could have a positive effect in terms of improving women's behavior and reducing seroconversion during pregnancy but strong evidence is still lacking. In settings where prenatal educative interventions are already in place, it could be beneficial to consider offering a specific session on how to avoid toxoplasmosis infection and provide printed materials that are informative.</P>
<P>A good surveillance system should be in place whenever a prenatal education activity is implemented to monitor the prevalence of seropositivity among pregnant women and to detect cases of congenital toxoplasmosis among the offspring of women who seroconverted during pregnancy.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-07-28 13:51:03 +0100" MODIFIED_BY="Heather Maxwell">
<P>Given the limited evidence supporting prenatal education for congenital toxoplasmosis prevention, further randomized controlled trials are needed. Given the nature of the intervention, those trials would most probably be cluster-randomized trials, that is a trial were groups rather than individuals are randomized between or among comparator interventions. The studies should focus on assessing the impact of different sets of intervention. The adequate sample size to detect a reduction of the incidence of congenital toxoplasmosis can be calculated considering at least two possible scenarios depending on the background incidence and hypothesized effect of intervention. In countries with a high incidence rate like Brazil (16/1000) (<LINK REF="REF-Reis-1999" TYPE="REFERENCE">Reis 1999</LINK>), and in countries with low incidence rate as in western Europe (10/10,000) (<LINK REF="REF-Gilbert-1999" TYPE="REFERENCE">Gilbert 1999</LINK>), predicting a 50% reduction of incidence in the intervention arm of the trial (<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>), considering a 95% confidence level and a 80% study power, and after doubling the sample to take in account the design effect of the cluster-randomized trial, the needed sample will be (<LINK REF="REF-EpiInfo-6" TYPE="REFERENCE">EpiInfo 6</LINK>):</P>
<OL>
<LI>countries with high incidence like Brazil: 6300 women per arm;</LI>
<LI>countries with low incidence as in western Europe: 102,000 women per arm.</LI>
</OL>
<P>As results from this raw calculation, only large studies will be able to detect a difference in terms of incidence of congenital toxoplasmosis; therefore, careful consideration should be given in valuing the balance between benefits and costs of such trials. Trials assessing the effect of a multilevel prenatal educational intervention also including toxoplasmosis prevention among others, and measuring the change in behavior or better pregnancy outcome as a composite outcome, might be more practical and preferable. Finally, we also suggest that in planning such trials, a checklist for good quality reporting of cluster-randomized trials, for example, a modified Consolidated Standards Of Reporting Trials (CONSORT) (<LINK REF="REF-Campbell-2004" TYPE="REFERENCE">Campbell 2004</LINK>), should be followed to ensure better quality and to provide valuable information.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-19 11:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>Nasreen Aflaifel for her support in the creation of the 'Summary of findings' tables for the 2015 update. Nasreen Aflaifel's work was financially supported by the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), World Health Organization. The named authors alone are responsible for the views expressed in this publication.</P>
<P>The World Health Organization and Simona Di Mario, Vittorio Basevi, Carlo Gagliotti, Daniela Spettoli, Gianfranco Gori and Roberto D'Amico retain copyright and all other rights in their respective contributions to the manuscript of this Review as submitted for publication.</P>
<P>We acknowledge Dr Chiara Bassi, CeVEAS, Modena, for designing and running the search strategy, and Dr Sara Balduzzi, Modena and Reggio Emilia University, for providing inputs and comments on the 2013 updated version of the review.</P>
<P>This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-05-18 16:50:43 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-28 13:51:10 +0100" MODIFIED_BY="Heather Maxwell">
<P>First version of the review: Simona Di Mario (SDM), Vittorio Basevi (VB) and Daniela Spettoli (DS) were responsible for the conception of the study. SDM, DS, Carlo Gagliotti (CG) and Gianfranco Gori selected the studies and assessed the quality. SDM, DS and CG collected and analyzed the data. VB, Nicola Magrini and Roberto D'Amico (RDA) provided input for writing the protocol and review. All authors provided comments on earlier drafts, revised and approved the initial version of the review. SDM, CG and RDA assessed the new studies for inclusion and performed the data extraction. SDM drafted the changes to the text. All authors provided comments, revised and approved the updated version of the review.</P>
<P>For the 2015 update, Simona Di Mario (SDM) rearranged the text of the review according to new standard suggested from the Cochrane Pregnancy and Childbirth Group, adding new paragraphs and additional other references; Vittorio Basevi (VB), Daniela Spettoli (DS) and Carlo Gagliotti (CG) revised the text, Gianfranco Gori (GG), Nicola Magrini (NM) and Roberto D'Amico (RDA) read and approved the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-07-28 13:51:16 +0100" MODIFIED_BY="Heather Maxwell">
<P>The methods have been updated to reflect the latest <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the current standard methods text of Cochrane Pregnancy and Childbirth Group. Two 'Summary of findings' tables have been incorporated.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-09-23 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-12-10 10:34:51 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-08-01 10:45:47 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-1989" NAME="Carter 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter AO, Gelmon SB, Wells GA, Toepell AP</AU>
<TI>The effectiveness of a prenatal education programme for the prevention of congenital toxoplasmosis</TI>
<SO>Epidemiology and Infection</SO>
<YR>1989</YR>
<VL>103</VL>
<PG>539-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wallon-2006" MODIFIED="2012-08-01 10:45:47 +0100" MODIFIED_BY="[Empty name]" NAME="Wallon 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-24 10:22:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gollub EL, Leroy V, Gilbert R, Chêne G, Wallon M; the European Toxoprevention Study Group (EUROTOXO)</AU>
<TI>Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy</TI>
<SO>European Journal of Obstetric &amp; Gynecology and Reproductive Biology</SO>
<YR>2008</YR>
<VL>136</VL>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-08-01 10:45:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="BOOK">
<AU>Nguyen DT</AU>
<SO>Evolution des connaissances et des comportements au cours d'un programme d'éducation prénatal pour la prévention primaire de la toxoplasmose congénitale chez les femmes enceintes séronégatif pour la toxoplasmose. Règion de Lyon, 1994-1995 [Impact on knowledge and behaviour of a prenatal education programme to prevent congenital toxoplasmosis among seronegative pregnant women. Lyon region, 1994-1995] [Masters thesis]</SO>
<YR>Juillet 2004</YR>
<PB>University of Bordeaux</PB>
<CY>Bordeaux</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-24 10:13:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wallon M, Nguyen Hoang Hanh DT, Peyron F, Chene G</AU>
<TI>Impact of health education for the primary prevention of toxoplasma infection in pregnancy: lessons from the ERIS study</TI>
<SO>16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2006 April 1-4; Nice, France</SO>
<YR>2006</YR>
<PG>Abstract no: P876</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-12-10 10:34:51 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Breugelmans-2004" MODIFIED="2012-12-10 10:34:51 +0000" MODIFIED_BY="[Empty name]" NAME="Breugelmans 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-12-10 10:34:51 +0000" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breugelmans M, Naessens A, Foulon W</AU>
<TI>Prevention of toxoplasmosis during pregnancy - an epidemiologic survey over 22 consecutive years</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>211-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-28 14:19:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Naessens A, Derde MP</AU>
<TI>Evaluation of the possibilities for preventing congenital toxoplasmosis</TI>
<SO>American Journal of Perinatology</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-28 14:19:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Naessens A, Lauwers S, De Meuter F, Amy JJ</AU>
<TI>Impact of primary prevention on the incidence of toxoplasmosis during pregnancy</TI>
<SO>Obstetrics &amp; Gynaecology</SO>
<YR>1988</YR>
<VL>72</VL>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mol_x00e9_-1992" MODIFIED="2008-10-28 14:19:17 +0000" MODIFIED_BY="[Empty name]" NAME="Molé 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-28 14:19:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molé JR, Suárez D, Alonso F, Piquera G</AU>
<TI>This is what we did to prevent congenital toxoplasmosis in Manzanillo</TI>
<TO>Lo que hacemos para prevenir la toxoplasmosis congénita en Manzanillo</TO>
<SO>Revista Cubana de Medicina General Integral</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>4</NO>
<PG>330-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pawlowski-2001" MODIFIED="2008-01-17 16:01:44 +0000" MODIFIED_BY="Lynn Hampson" NAME="Pawlowski 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-01-17 16:01:44 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pawlowski ZS, Gromadecka-Sutkiewicz M, Skommer J, Paul M, Rokossowski H, Suchocka E, et al</AU>
<TI>Impact of health education on knowledge and prevention behavior for congenital tooplasmosis: the experience in Poznan, Poland</TI>
<SO>Health Education Research</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>4</NO>
<PG>493-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-01-24 10:13:49 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-09-23 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-09-23 14:11:13 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alfirevic-2003" MODIFIED="2011-10-13 14:20:10 +0100" MODIFIED_BY="Lynn Hampson" NAME="Alfirevic 2003" TYPE="COCHRANE_REVIEW">
<AU>Alfirevic Z, Sundberg K, Brigham S</AU>
<TI>Amniocentesis and chorionic villus sampling for prenatal diagnosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-10-13 14:20:10 +0100" MODIFIED_BY="Lynn Hampson">
<IDENTIFIER MODIFIED="2011-10-13 14:20:10 +0100" MODIFIED_BY="Lynn Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD003252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Allain-1998" MODIFIED="2008-10-27 13:01:07 +0000" MODIFIED_BY="[Empty name]" NAME="Allain 1998" TYPE="JOURNAL_ARTICLE">
<AU>Allain JP, Palmer CR, Pearson G</AU>
<TI>Epidemiological study of latent and recent infection by toxoplasma gondii in pregnant women from a regional population in the UK</TI>
<SO>Journal of Infection</SO>
<YR>1998</YR>
<VL>36</VL>
<PG>189-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bader-1997" MODIFIED="2012-12-10 10:35:55 +0000" MODIFIED_BY="Heather Maxwell" NAME="Bader 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bader TJ, Macones GA, Asch DA</AU>
<TI>Prenatal screening for toxoplasmosis</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1997</YR>
<VL>90</VL>
<PG>457-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyer-2005" MODIFIED="2012-12-10 10:36:21 +0000" MODIFIED_BY="Heather Maxwell" NAME="Boyer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, et al</AU>
<TI>Risk factors for toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<PG>564-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2004" MODIFIED="2008-11-04 10:00:48 +0000" MODIFIED_BY="[Empty name]" NAME="Campbell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Campbell MK, Elbourne DR, Altman DG for the CONSORT Group</AU>
<TI>CONSORT statement: extension to cluster randomised trials</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>702-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chabbert-2004" MODIFIED="2012-12-10 10:36:38 +0000" MODIFIED_BY="Heather Maxwell" NAME="Chabbert 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chabbert E, Lachaud L, Crobu L, Bastien P</AU>
<TI>Comparison of two widely used PCR primer systems for detection of toxoplasma in amniotic fluid, blood, and tissues</TI>
<SO>Clinical Microbiology</SO>
<YR>2004</YR>
<VL>42</VL>
<PG>1719-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chamberlain-2013" MODIFIED="2015-06-11 23:47:21 +0100" MODIFIED_BY="[Empty name]" NAME="Chamberlain 2013" TYPE="COCHRANE_REVIEW">
<AU>Chamberlain C, O&#8217;Mara-Eves A, Oliver S, Caird JR, Perlen SM, Eades SJ, et al</AU>
<TI>Psychosocial interventions for supporting women to stop smoking in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2015-06-11 23:47:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-11 23:47:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001055.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cook-2000" MODIFIED="2012-12-10 10:36:53 +0000" MODIFIED_BY="[Empty name]" NAME="Cook 2000" TYPE="JOURNAL_ARTICLE">
<AU>Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, et al</AU>
<TI>Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis</TI>
<SO>BMJ</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>142-7</PG>
<IDENTIFIERS MODIFIED="2008-10-28 14:20:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-1999" MODIFIED="2008-10-27 13:02:51 +0000" MODIFIED_BY="[Empty name]" NAME="Dunn 1999" TYPE="JOURNAL_ARTICLE">
<AU>Dunn D</AU>
<TI>Mother to child transmission of toxoplasmosis: risks estimates or clinical counselling</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>1829-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EpiInfo-6" MODIFIED="2008-10-27 13:54:01 +0000" MODIFIED_BY="[Empty name]" NAME="EpiInfo 6" TYPE="COMPUTER_PROGRAM">
<AU>Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, et al</AU>
<TI>EpiInfo, Version 6: a word processing, database, and statistics programs for epidemiology on microcomputers</TI>
<YR>1994</YR>
<PB>Centers for Disease Control and Prevention</PB>
<CY>Atlanta</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2011" MODIFIED="2012-03-28 09:19:43 +0100" MODIFIED_BY="[Empty name]" NAME="Ferguson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson W, Mayne PD, Cafferkey M, Butler K</AU>
<TI>Lack of awareness of risk factors for primary toxoplasmosis in pregnancy</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>2011</YR>
<VL>180</VL>
<PG>807-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foulon-1988" MODIFIED="2012-04-04 15:29:20 +0100" MODIFIED_BY="[Empty name]" NAME="Foulon 1988" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Naessens A, Lauwers S, De Meuter F, Amy JJ</AU>
<TI>Impact of primary prevention on the incidence of toxoplasmosis during pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>1988</YR>
<VL>72</VL>
<PG>363-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foulon-1994" MODIFIED="2008-11-07 13:34:04 +0000" MODIFIED_BY="[Empty name]" NAME="Foulon 1994" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Naessens A, Derde MP</AU>
<TI>Evaluation of the possibilities for preventing congenital toxoplasmosis</TI>
<SO>American Journal of Perinatology</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foulon-1999a" MODIFIED="2012-12-10 10:38:57 +0000" MODIFIED_BY="Heather Maxwell" NAME="Foulon 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Villena I, Stray-Pederson B, Decoster A, Lappalainen M, Pinon JM, et al</AU>
<TI>Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children sequelae at age 1 year</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>180</VL>
<PG>410-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foulon-1999b" MODIFIED="2012-12-10 10:39:10 +0000" MODIFIED_BY="Heather Maxwell" NAME="Foulon 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Pinon JM, Stray-Pederson B, Pollak A, Lappalainen M, Decoster A, et al</AU>
<TI>Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>181</VL>
<PG>843-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foulon-2000" MODIFIED="2015-06-16 11:31:12 +0100" MODIFIED_BY="[Empty name]" NAME="Foulon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Foulon W, Naessens A, Ho-Yen D</AU>
<TI>Prevention of congenital toxoplasmosis</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>337-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-1999" MODIFIED="2012-12-10 10:39:57 +0000" MODIFIED_BY="[Empty name]" NAME="Gilbert 1999" TYPE="BOOK_SECTION">
<AU>Gilbert RE</AU>
<TI>Epidemiology of infection in pregnant women</TI>
<SO>Congenital Toxoplasmosis: Scientific Background, Clinical Management and Control</SO>
<YR>1999</YR>
<ED>Petersen E, Amboise-Thomas P</ED>
<PB>Springer-Verlag France</PB>
<CY>Paris</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2001" MODIFIED="2008-10-28 14:21:52 +0000" MODIFIED_BY="[Empty name]" NAME="Gilbert 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert R, Dunn D, Wallon M, Hayde M, Prusa A, Lebech M, et al</AU>
<TI>Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol</TI>
<SO>Epidemiology and Infection</SO>
<YR>2001</YR>
<VL>127</VL>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2002" MODIFIED="2012-12-10 10:40:13 +0000" MODIFIED_BY="Heather Maxwell" NAME="Gilbert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert RE, Peckham CS</AU>
<TI>Congenital toxoplasmosis in the United Kingdom: to screen or not to screen?</TI>
<SO>Journal of Medical Screening</SO>
<YR>2002</YR>
<VL>9</VL>
<PG>135-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2003" MODIFIED="2008-11-04 10:01:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gilbert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert R, Gras L</AU>
<TI>European multicentre study on congenital toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2003</YR>
<VL>110</VL>
<PG>112-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2007" NAME="Gilbert 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert RE, Thalib L, Tan HK, Paul M, Wallon M, Petersen E</AU>
<TI>Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth</TI>
<SO>Journal of Medical Screening</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golloub-2008" MODIFIED="2015-06-16 11:31:46 +0100" MODIFIED_BY="[Empty name]" NAME="Golloub 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gollub EL, Leroy V, Gilbert R, Chêne G, Wallon M; European ToxopreventionStudy Group (EUROTOXO)</AU>
<TI>Effectiveness of health education on Toxoplasma-relatedknowledge, behaviour, and risk of seroconversion in pregnancy</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2008</YR>
<VL>136</VL>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hahn-2005" MODIFIED="2008-10-28 14:39:48 +0000" MODIFIED_BY="[Empty name]" NAME="Hahn 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hahn S, Puffer S, Torgerson DJ, Watson J</AU>
<TI>Methodological bias in cluster randomised trials</TI>
<SO>BMC Medical Research Methodology </SO>
<YR>2005</YR>
<VL>5</VL>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-28 09:26:24 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lebech-1996" MODIFIED="2012-12-10 10:47:22 +0000" MODIFIED_BY="Heather Maxwell" NAME="Lebech 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lebech M, Joynson DH, Seitz HM, Thulliez P, Gilbert RE, Dutton GN, et al</AU>
<TI>Classification system and case definitions of toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis</TI>
<SO>European Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1996</YR>
<VL>15</VL>
<PG>799-805</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lebech-1999" MODIFIED="2012-12-10 10:47:37 +0000" MODIFIED_BY="Heather Maxwell" NAME="Lebech 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lebech M, Andersen O, Christensen NC, Hertel J, Nielsen HE, Petersen B, et al</AU>
<TI>Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>1834-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liesenfeld-1997" MODIFIED="2008-11-04 10:03:02 +0000" MODIFIED_BY="[Empty name]" NAME="Liesenfeld 1997" TYPE="JOURNAL_ARTICLE">
<AU>Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, et al</AU>
<TI>False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia toxo IgM test</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1997</YR>
<VL>35</VL>
<PG>174-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montoya-2004" MODIFIED="2012-12-10 10:49:15 +0000" MODIFIED_BY="Heather Maxwell" NAME="Montoya 2004" TYPE="JOURNAL_ARTICLE">
<AU>Montoya JG, Liesenfeld O</AU>
<TI>Toxoplasmosis</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>1965-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nguyen-2004" MODIFIED="2015-06-16 11:32:07 +0100" MODIFIED_BY="[Empty name]" NAME="Nguyen 2004" TYPE="OTHER">
<AU>Nguyen DT</AU>
<TI>Evolution of knowledge and behavior during a prenatal education program for primary prevention of congenital toxoplasmosis in pregnant women seronegative for toxoplasmosis</TI>
<TO>Evolution des connaissances et des comportements au cours d&#8217;un programme d&#8217;éducation prénatal pour la prévention primaire de la toxoplasmose congénitale chez les femmes enceintes séronégatif pour la toxoplasmose</TO>
<SO>Région de Lyon, 1994&#8211;1995. Juillet 2004</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NSC-2001" MODIFIED="2012-12-10 10:49:21 +0000" MODIFIED_BY="[Empty name]" NAME="NSC 2001" TYPE="BOOK">
<AU>National Screening Committee Working Group</AU>
<SO>Antenatal and Newborn Screening for Toxoplasmosis. Report of the Working Group -- October 2001</SO>
<YR>2001</YR>
<PB>National Screening Committee</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peyron-1999" MODIFIED="2011-10-13 14:20:16 +0100" MODIFIED_BY="Lynn Hampson" NAME="Peyron 1999" TYPE="COCHRANE_REVIEW">
<AU>Peyron F, Wallon M, Liou C, Garner P</AU>
<TI>Treatments for toxoplasmosis in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-10-13 14:20:16 +0100" MODIFIED_BY="Lynn Hampson">
<IDENTIFIER MODIFIED="2011-10-13 14:20:16 +0100" MODIFIED_BY="Lynn Hampson" TYPE="DOI" VALUE="10.1002/14651858.CD001684"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Puffer-2003" MODIFIED="2012-04-04 15:30:31 +0100" MODIFIED_BY="[Empty name]" NAME="Puffer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Puffer S, Torgerson D, Watson J</AU>
<TI>Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>785-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reis-1999" MODIFIED="2008-11-05 11:36:50 +0000" MODIFIED_BY="[Empty name]" NAME="Reis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Reis R, Lösch R, Lago EG</AU>
<TI>Primary prevention of congenital toxoplsmosis</TI>
<TO>Prevenção primária da toxoplasmose congênita</TO>
<SO>Acta Médica</SO>
<YR>1999</YR>
<VL>20</VL>
<PG>704-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-01-14 15:12:15 +0000" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rorman-2006" NAME="Rorman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rorman E, Stein Zamir C, Rilkis I, Ben-David H</AU>
<TI>Congenital toxoplasmosis - prenatal aspects of toxoplasma gondii infection</TI>
<SO>Reproductive Toxicology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>4</NO>
<PG>458-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmidt-2006" NAME="Schmidt 2006" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt DR, Hogh B, Andersen O, Fuchs J, Fledelius H, Petersen E</AU>
<TI>The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>661-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Signorell-2006" MODIFIED="2008-01-17 16:09:05 +0000" MODIFIED_BY="Lynn Hampson" NAME="Signorell 2006" TYPE="JOURNAL_ARTICLE">
<AU>Signorell LM, Seitz D, Merkel S, Berger R, Rudin C</AU>
<TI>Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982-1999</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>123-8</PG>
<IDENTIFIERS MODIFIED="2008-01-17 16:09:01 +0000" MODIFIED_BY="Lynn Hampson"/>
</REFERENCE>
<REFERENCE ID="REF-SYROCOT-2007" NAME="SYROCOT 2007" TYPE="JOURNAL_ARTICLE">
<AU>Thiébaut R, Leproust S, Chêne G, Gilbert R</AU>
<TI>Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>369</VL>
<PG>115-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thalib-2005" MODIFIED="2012-12-10 10:49:27 +0000" MODIFIED_BY="Heather Maxwell" NAME="Thalib 2005" TYPE="JOURNAL_ARTICLE">
<AU>Thalib L, Gras L, Romand S, Prusa A, Bessieres MH, Petersen E, et al</AU>
<TI>Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>567-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Torgerson-2001" MODIFIED="2008-11-04 10:03:25 +0000" MODIFIED_BY="[Empty name]" NAME="Torgerson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Torgerson DJ</AU>
<TI>Contamination in trials: is cluster randomisation the answer?</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1980" MODIFIED="2008-10-27 13:10:53 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Wilson CB, Remington JS, Stagno S, Reynolds DW</AU>
<TI>Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection</TI>
<SO>Pediatrics</SO>
<YR>1980</YR>
<VL>66</VL>
<PG>767-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-28 11:28:24 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Di-Mario-2006" MODIFIED="2015-07-28 11:28:24 +0100" MODIFIED_BY="Heather Maxwell" NAME="Di Mario 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Di Mario S, Basevi V, Gagliotti C, Spettoli D, Gori G, D'Amico R, et al</AU>
<TI>Prenatal education for congenital toxoplasmosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-12-10 11:05:39 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-12-10 11:05:39 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006171"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Di-Mario-2009" MODIFIED="2015-07-28 11:26:53 +0100" MODIFIED_BY="Heather Maxwell" NAME="Di Mario 2009" TYPE="COCHRANE_REVIEW">
<AU>Di Mario S, Basevi V, Gagliotti C, Spettoli D, Gori G, D'Amico R, et al</AU>
<TI>Prenatal education for congenital toxoplasmosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-12-10 11:02:08 +0000" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-12-10 11:02:08 +0000" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006171.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Di-Mario-2013" MODIFIED="2015-07-28 11:26:07 +0100" MODIFIED_BY="Heather Maxwell" NAME="Di Mario 2013" TYPE="COCHRANE_REVIEW">
<AU>Di Mario S, Basevi V, Gagliotti C, Spettoli D, Gori G, D'Amico R, Magrini N</AU>
<TI>Prenatal education for congenital toxoplasmosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-01-14 15:13:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-14 15:13:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006171.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-28 11:38:47 +0100" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-07-28 11:38:47 +0100" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-07-28 11:36:37 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Carter-1989">
<CHAR_METHODS MODIFIED="2012-01-24 10:56:19 +0000" MODIFIED_BY="[Empty name]">
<P>Cluster-randomized trial. Unit of randomization was the antenatal class.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-04-18 15:12:25 +0100" MODIFIED_BY="[Empty name]">
<P>432 pregnant women attending 52 prenatal classes offered for free by a public health agency in Ontario. Completed both the pre-test and the post-test questionnaire 285 women (122 in the experimental arm and 163 in the control arm). Loss to follow-up was 34%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-05-06 13:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>10-minute teaching session during the first prenatal class on how to avoid toxoplasmosis infection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-04 10:04:56 +0000" MODIFIED_BY="[Empty name]">
<P>Pet hygiene behavior of cat owners.<BR/>Food hygiene behaviors.<BR/>Personal hygiene behaviors.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-28 11:36:37 +0100" MODIFIED_BY="Heather Maxwell">
<P>A behavior change scoring system was developed: a woman gained 1 point for every change toward a useful behavior, while she lost 1 point for every change toward a dangerous behavior.</P>
<P>The authors did not report raw data (number or proportion): only the significance test data (P value) for differences were reported. We have contacted the authors for the original data but have not yet received a reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-28 11:38:47 +0100" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Wallon-2006">
<CHAR_METHODS MODIFIED="2015-07-28 11:38:47 +0100" MODIFIED_BY="Heather Maxwell">
<P>Cluster-randomized trial. Units of randomization were prenatal clinics.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-12-11 09:23:24 +0000" MODIFIED_BY="[Empty name]">
<P>5023 seronegative pregnant women attending prenatal clinics in 7 counties in the area of Lyon (France). Completed both the pre-test and the post-test questionnaire 2790 women (1953 in the experimental arm and 837 in the control arm). Loss to follow-up was 44.5%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-04-18 15:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>Physicians in experimental cities were instructed to give their patients:</P>
<P>- a 20-page brochure containing relevant information about different aspects of pregnancy, including 4 pages on toxoplasmosis prevention and transmission;</P>
<P>- an audiotape containing frequently asked questions during pregnancy, including questions on toxoplasmosis.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-12-10 11:38:27 +0000" MODIFIED_BY="[Empty name]">
<P>Knowledge and behavior change including:</P>
<P>- consumption of undercooked meat of any type;</P>
<P>- handwashing after contact with transmission factors (soil, raw meat, unwashed vegetables) and before meals.</P>
<P>Seroconvertion for toxoplasmosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-10 11:38:35 +0000" MODIFIED_BY="[Empty name]">
<P>Knowledge and behavior was measured through a questionnaire at baseline (during the third and fourth months of pregnancy) and at follow-up (at delivery).</P>
<P>There was a large and differential loss-to-follow-up: completed the follow-up questionnaire and were therefore included in the analysis 60% of the women enrolled in the experimental group and 48% of the women enrolled in the control group. A multivariate analysis was conducted but it was not specified if the statistical plan of analysis considered to correct for cluster design.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-05-25 12:16:01 +0100" MODIFIED_BY="Sonja L Henderson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-05-25 12:15:57 +0100" MODIFIED_BY="Sonja L Henderson" STUDY_ID="STD-Breugelmans-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-25 12:15:57 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Not randomized. For details of study, <I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-25 12:15:59 +0100" MODIFIED_BY="Sonja L Henderson" STUDY_ID="STD-Mol_x00e9_-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-25 12:15:59 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Not randomized. For details of study, <I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-05-25 12:16:01 +0100" MODIFIED_BY="Sonja L Henderson" STUDY_ID="STD-Pawlowski-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-05-25 12:16:01 +0100" MODIFIED_BY="Sonja L Henderson">
<P>Not randomized. For details of study, <I>see</I> <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-01-24 10:13:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-07-28 11:37:04 +0100" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-12-11 09:16:04 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-11 09:15:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Not described in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-11 09:16:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Not described in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-07-28 11:37:04 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-28 11:37:04 +0100" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Not described in the publication. However, as all the centers present in that jurisdictional area were involved, an equal number of classes in each center received the experimental and the control intervention, and this is a cluster-randomized trial, thus the units of randomization are the prenatal groups, the lack of allocation concealment is unlikely to influence the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-11 09:16:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Not described in the publication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-12-11 09:16:06 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-12-11 09:15:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Blinding of the women reported, blinding of the personnel was not possible, but unlikely to influence the outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-12-11 09:16:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Blinding of the women reported, blinding of the personnel was not possible, but unlikely to influence the outcome as the outcome assessed by the personnel was seroconversion rate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-12-11 09:16:07 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-12-11 09:15:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Measure of knowledge and behavior were self-reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-12-11 09:16:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Measure of knowledge and behavior were self-reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-12-11 09:16:08 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-11 09:15:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Losses to follow-up were 34% (432 women completed the pretest questionnaire and 285 completed the post-test questionnaire): women in experimental group were more likely to be lost at follow-up than women in control group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-11 09:16:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Overall losses to follow-up were 44.5%: women in the control group were more likely to be lost at follow-up (52% were lost) than women in intervention group (40% were lost).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-05-29 13:00:44 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-29 13:00:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>All of the pre-specified outcomes have been reported. However, the study did not report seroconversion rate during pregnancy, which is an outcome of interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-11 09:16:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>All of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review (including seroconversion rate) have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-12-11 09:15:50 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-11 09:15:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carter-1989">
<DESCRIPTION>
<P>Contamination between groups can not be excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-18 09:40:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wallon-2006">
<DESCRIPTION>
<P>Study method and statistical plan of analysis were not described in details, therefore it is not possible to exclude other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-06-29 13:49:45 +0100" MODIFIED_BY="Leanne V Jones" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-23 12:56:44 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-23 09:59:45 +0100" MODIFIED_BY="Sonja L Henderson" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-07-28 11:42:50 +0100" MODIFIED_BY="Heather Maxwell">Educational prenatal classes compared with usual prenatal classes for prenatal education for congenital toxoplasmosis</TITLE>
<TABLE COLS="2" ROWS="10">
<TR>
<TD COLSPAN="2">
<P>
<B>Educational prenatal classes compared with usual prenatal classes for prenatal education for congenital toxoplasmosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Patient or population: </B>women of reproductive age, irrespective of their pregnant status<BR/>
<B>Settings: </B>Ontario, Canada<BR/>
<B>Intervention: </B>educational prenatal classes<BR/>
<B>Comparison: </B>usual prenatal classes</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rate of congenital toxoplasmosis, defined by persistence of specific IgG antibodies beyond 11 months of age</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="5" VALIGN="TOP">
<P/>
<P/>
<P/>
<P>These outcomes were either not reported or were reported in unusable formate for 'Summary of findings' tables.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rate of toxoplasmosis seroconversion in pregnant women</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women knowledge of risk factors for acquiring toxoplasmosis infection as objectively measured through specific questionnaire</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women's awareness of the importance of avoiding toxoplasmosis during pregnancy as objectively measured through specific questionnaire</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women behavior with respect to the avoidance of risk factors for toxoplasmosis infection during pregnancy as objectively measured through specific questionnaire</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-09-23 12:56:44 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2015-07-28 11:50:08 +0100" MODIFIED_BY="Heather Maxwell">Brochure and an audiotape compared with standard care for prenatal education for congenital toxoplasmosis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Brochure and an audiotape compared with standard care for prenatal education for congenital toxoplasmosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>women of reproductive age, irrespective of their pregnant status<BR/>
<B>Settings: </B>France<BR/>
<B>Intervention: </B>brochure and an audiotape<BR/>
<B>Comparison: </B>standard care</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Standard care</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>brochure and an audiotape</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Rate of toxoplasmosis seroconversion in pregnant women</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.70<BR/>(0.56 to 5.21)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>3949<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>3 per 1000</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>5 per 1000<BR/>(2 to 15)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women behavior with respect to the avoidance of risk factors for toxoplasmosis infection during pregnancy (no consumption of uncooked meat of any type)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OR 1.21<BR/>(0.98 to 1.50)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>MODERATE <SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Events were not available for these two outcomes. OR for these two outcomes were obtained from a review that included this study.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women behavior with respect to the avoidance of risk factors for toxoplasmosis during pregnancy (hand washing after contact with transmission factor and before meals)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>OR 1.01<BR/>(0.38 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW <SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rate of congenital toxoplasmosis defined by persistence of IgG antibodies beyond 11 months</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="3" VALIGN="TOP">
<P/>
<P>None of these outcomes were reported in the included study. If in future updates data on these outcomes are available we will include them in this SOF.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women knowledge of risk factors for acquiring toxoplasmosis infection as objectively measured through specific questionnaire</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pregnant women awareness of the importance of avoiding toxoplasmosis infection during pregnancy as objectively measured through specific questionnaire</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI: </B>Confidence interval; <B>OR:</B> odds ratio; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality: </B>Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality: </B>Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality: </B>Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality: </B>We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Evidence from one study with high risk of bias</P>
<P>
<SUP>2</SUP>Wide CI crossing the line of no effect</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-07-28 12:15:52 +0100" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-07-28 12:15:52 +0100" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE>Description of the excluded studies</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TH>
<P>Reference</P>
</TH>
<TH>
<P>Study design/Method</P>
</TH>
<TH>
<P>Setting/Participants</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Results</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Breugelmans-2004" TYPE="STUDY">Breugelmans 2004</LINK>
</P>
</TD>
<TD>
<P>Prospective survey during 3 study periods.<BR/>Pre-post study.<BR/>
<BR/>Serological test (IgG and IgM against toxoplasma) at first prenatal visit. Seronegative women were retested every 6 weeks, in addition, a test on cord blood was done at birth.<BR/>
<BR/>Definition of seroconversion: women initially IgG negative with subsequent IgG detection.</P>
</TD>
<TD>
<P>Belgium. Hospital setting.<BR/>
<BR/>23 years of observation (from 1979 to 2001).<BR/>
<BR/>27,827 pregnant women:<BR/>2986 pregnant women before the intervention;<BR/>8300 pregnant women after the first round of intervention;<BR/>16,541 pregnant women after the second round of intervention.<BR/>
</P>
</TD>
<TD>
<P>First period (from 1979 to 1982): control. Incidence of toxoplasmosis studied in 2986 consecutive pregnant women.<BR/>Second period (from 1983 to 1990): first round of intervention. 8300 pregnant women received at first prenatal visit, and subsequently during monthly antenatal classes, a list of recommendations to avoid toxoplasma infection.<BR/>Third period (from 1991 to 2001): second round of intervention. 16,541 pregnant women received leaflets explaining what toxoplasmosis is and what measures should be taken to avoid it in pregnancy. Reiteration of the information during antenatal classes.<BR/>
</P>
</TD>
<TD>
<P>Seroconversion rate during pregnancy.<BR/>
<BR/>
<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>I period: 1.43%.<BR/>II period: 0.53%.<BR/>III period: 0.09%.<BR/>
<BR/>
</P>
</TD>
<TD>
<P>In this population the incidence of toxoplasmosis in pregnancy is 8/1,000 pregnancies, and the prevalence of congenital toxoplasmosis is 2/1,000 live births.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mol_x00e9_-1992" TYPE="STUDY">Molé 1992</LINK>
</P>
</TD>
<TD>
<P>Intervention study; the definition of the control group, if any, is not reported in the abstract.</P>
<P>Serological test at first prenatal visit. Seronegative women were regularly retested. An educational intervention on how to avoid infection during pregnancy was provided to all seronegative pregnant women.</P>
</TD>
<TD>
<P>Cuba. Hospital and ambulatory setting of 4 municipalities in Manzanillo.</P>
<P/>
<P>2058 pregnant women.</P>
</TD>
<TD>
<P>Prenatal education on how to avoid toxoplasmosis infection during pregnancy was delivered to seronegative pregnant women (84% of the total sample).</P>
<P/>
</TD>
<TD>
<P>Seroconversion rate during pregnancy.</P>
</TD>
<TD>
<P>1.38%.</P>
</TD>
<TD>
<P>Full text of the article not available. Data reported here have been obtained from the published abstract.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pawlowski-2001" TYPE="STUDY">Pawlowski 2001</LINK>
</P>
</TD>
<TD>
<P>Survey during 2 study periods. Pre-post study.<BR/>
<BR/>Questionnaire about knowledge of toxoplasmosis and correct behavior administered to pregnant women in 1991 to 1992 and 1997.</P>
</TD>
<TD>
<P>Poland. Hospital setting.<BR/>
<BR/>4311 pregnant women in the first period (1991 to 1992); 2710 women in the second period (1997).</P>
</TD>
<TD>
<P>Starting from 1991 various educational activities were implemented (training of health professionals, printed material given to pregnant women, mass media campaign, school education programs).</P>
</TD>
<TD>
<P>Good knowledge of toxoplasmosis in pregnant women.<BR/>
<BR/>Correct behavior in pregnant women.</P>
</TD>
<TD>
<P>I period: 24.3%.<BR/>II period: 45.3%.<BR/>
<BR/>II period: 55.2%.</P>
</TD>
<TD>
<P>It is not possible to compare the change in correct behavior, measured only in the second survey in 1997.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-05-13 12:45:52 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-05-13 12:45:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Brochure and an audiotape compared to standard care</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.214019993739723" CI_START="0.5564917671626026" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7033963720571208" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.717172692186009" LOG_CI_START="-0.25454125631094415" LOG_EFFECT_SIZE="0.23131571793753244" METHOD="MH" MODIFIED="2015-05-13 12:45:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3507499320318228" Q="0.0" RANDOM="NO" SCALE="211.97" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2591" TOTAL_2="1358" WEIGHT="100.0" Z="0.933135676228303">
<NAME>Rate of toxoplasmosis seroconversion during pregnancy</NAME>
<GROUP_LABEL_1>Brochure and an audiotape</GROUP_LABEL_1>
<GROUP_LABEL_2>Standard care</GROUP_LABEL_2>
<GRAPH_LABEL_1>Standard care</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Brochure and an audiotape</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.214019993739723" CI_START="0.5564917671626026" EFFECT_SIZE="1.7033963720571208" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.717172692186009" LOG_CI_START="-0.25454125631094415" LOG_EFFECT_SIZE="0.23131571793753244" MODIFIED="2015-05-12 12:33:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.5707895834087311" STUDY_ID="STD-Wallon-2006" TOTAL_1="2591" TOTAL_2="1358" VAR="0.32580074852791274" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-28 11:37:05 +0100" MODIFIED_BY="Heather Maxwell">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-08-01 10:54:31 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeYAAANCCAYAAACzgW8eAAB7+0lEQVR42uy9AWSW3////yVJkkTy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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-07-28 11:37:05 +0100" MODIFIED_BY="Heather Maxwell" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-07-28 11:37:05 +0100" MODIFIED_BY="Heather Maxwell" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAAGRCAIAAABt2XjvAAARsUlEQVR42u3dvY5cRRPG8ZWQEMEG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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-07-28 13:33:09 +0100" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2012-08-01 11:12:24 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-01-17 15:45:04 +0000" MODIFIED_BY="Lynn Hampson">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-01 11:12:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Search strategies written and run by authors:</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">PubMed (1966 to 15 January 2012):</HEADING>
<P>#1. toxoplasm*<BR/>#2. 'toxoplasma'/exp<BR/>#3. 'toxoplasmosis'/exp<BR/>#4. #1 OR #2 OR #3<BR/>#5. neonat*<BR/>#6. antenat*<BR/>#7. infant*<BR/>#8. ('baby'/exp OR 'baby')<BR/>#9. babies<BR/>#10. foet*<BR/>#11. fetus<BR/>#12. fetal*<BR/>#13. p?ediatr*<BR/>#14. prenat*<BR/>#15. 'infant'/exp<BR/>#16. 'fetus'/exp<BR/>#17. 'pediatrics'/exp<BR/>#18. OR/ #5-#17<BR/>#19. #4 AND #18<BR/>#20.'mass media'/exp OR 'mass media'<BR/>#21. communication*<BR/>#22. multimedia*<BR/>#23. 'multi media'<BR/>#24. 'multimedia'/exp<BR/>#25. 'mass communication'<BR/>#26. ('audiovisual equipment'/exp OR 'audiovisual equipment')<BR/>#27. ('patient information'/exp OR 'patient information')<BR/>#28. ('visual information'/exp OR 'visual information')<BR/>#29. ('radio'/exp OR 'radio')<BR/>#30. ('television'/exp OR 'television')<BR/>#31. leaflet*<BR/>#32. poster*<BR/>#33. pamphlet*<BR/>#34. 'print media'<BR/>#35. 'printed media'<BR/>#36. 'broadcast'<BR/>#37. film*<BR/>#38. ('telecommunication'/exp OR telecommunication*)<BR/>#39. counsel*<BR/>#40. educat*<BR/>#41. empower*<BR/>#42. knowledge*<BR/>#43. skill*<BR/>#44. 'public health'/exp<BR/>#45. 'preventive medicine'/exp<BR/>#46. 'preventive health service'/exp<BR/>#47. 'primary health care'/exp<BR/>#48. 'health care delivery'/exp<BR/>#49. 'patient attitude'/exp<BR/>#50. 'primary prevention'/exp<BR/>#51. 'health promotion'/exp<BR/>#52. 'health education'/exp<BR/>#53. 'patient education'/exp<BR/>#54. 'education'/exp<BR/>#55. 'attitude'/exp<BR/>#56. 'cognition'/exp<BR/>#57. 'health behavior'/exp<BR/>#58. 'decision making'/exp<BR/>#59 OR/#20-#58<BR/>#60 #19 AND #59</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">EMBASE (Embase.com) (1980 to 15 January 2012)</HEADING>
<P>#1. toxoplasm*<BR/>#2. 'toxoplasma'/exp<BR/>#3. 'toxoplasmosis'/exp<BR/>#4. #1 OR #2 OR #3<BR/>#5. neonat*<BR/>#6. antenat*<BR/>#7. infant*<BR/>#8. ('baby'/exp OR 'baby')<BR/>#9. babies<BR/>#10. foet*<BR/>#11. fetus<BR/>#12. fetal*<BR/>#13. p?ediatr*<BR/>#14. prenat*<BR/>#15. 'infant'/exp<BR/>#16. 'fetus'/exp<BR/>#17. 'pediatrics'/exp<BR/>#18. OR/ #5-#17<BR/>#19. #4 AND #18<BR/>#20.'mass medium'/exp OR 'mass media'<BR/>#21. communication*<BR/>#22. multimedia*<BR/>#23. 'multi media'<BR/>#24. 'mass communication'<BR/>#25. ('audiovisual equipment'/exp OR 'audiovisual equipment')<BR/>#26. ('patient information'/exp OR 'patient information')<BR/>#27. ('visual information'/exp OR 'visual information')<BR/>#28. radio<BR/>#29. ('television'/exp OR 'television')<BR/>#30. leaflet*<BR/>#31. poster*<BR/>#32. pamphlet*<BR/>#33. 'print media'<BR/>#34. 'printed media'<BR/>#35. 'broadcast'<BR/>#36. film*<BR/>#37. ('telecommunication'/exp OR telecommunication*)<BR/>#38. counsel*<BR/>#39. educat*<BR/>#40. empower*<BR/>#41. knowledge*<BR/>#42. skill*<BR/>#43. 'public health'/exp<BR/>#44. 'preventive medicine'/exp<BR/>#45. 'preventive health service'/exp<BR/>#46. 'primary health care'/exp<BR/>#47. 'health care delivery'/exp<BR/>#48. 'patient attitude'/exp<BR/>#49. 'primary prevention'/exp<BR/>#50. 'health promotion'/exp<BR/>#51. 'health education'/exp<BR/>#52. 'patient education'/exp<BR/>#53. 'education'/exp<BR/>#54. 'attitude'/exp<BR/>#55. 'cognition'/exp<BR/>#56. 'health behavior'/exp<BR/>#57. 'decision making'/exp<BR/>#58 OR/#20-#57<BR/>#59 #19 AND #58</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">CINAHL (via EBSCO) (1982 to 15 January 2012)</HEADING>
<P>#1. toxoplasm*<BR/>#2. MH 'toxoplasmosis'<BR/>#3. #1 OR #2<BR/>#4. neonat*<BR/>#5. antenat*<BR/>#6. infant*<BR/>#7. baby<BR/>#8. babies<BR/>#9. foet*<BR/>#10. fetus<BR/>#11. fetal*<BR/>#12. p?ediatr*<BR/>#13. prenat*<BR/>#14. MH 'infant'<BR/>#15. MH 'fetus'<BR/>#16. MH 'pediatrics'<BR/>#17. OR/ #4-#16<BR/>#18. #3 AND #17<BR/>#19. MH 'communication media' OR 'mass media'<BR/>#20. communication*<BR/>#21. multimedia*<BR/>#22. 'multi media'<BR/>#23. 'mass communication'<BR/>#24. MH 'audiovisuals' OR 'audiovisual equipment'<BR/>#25. 'patient information'<BR/>#26. 'visual information'<BR/>#27. MH 'radio' OR 'radio'<BR/>#28. MH 'television' OR 'television'<BR/>#29. leaflet*<BR/>#30. poster*<BR/>#31. pamphlet*<BR/>#32. 'print media'<BR/>#33. 'printed media'<BR/>#34. 'broadcast'<BR/>#35. film*<BR/>#36. MH 'telecommunications' OR telecommunication*<BR/>#37. counsel*<BR/>#38. educat*<BR/>#39. empower*<BR/>#40. knowledge*<BR/>#41. skill*<BR/>#42. 'public health'/exp<BR/>#43. MH 'preventive health care'<BR/>#44. MH 'primary health care'<BR/>#45. MH 'health care delivery'<BR/>#46. MH 'patient attitudes'<BR/>#47. MH 'primary prevention'<BR/>#48. MH 'health services needs and demand&#8217;<BR/>#49. MH 'health education'<BR/>#50. MH 'patient education'<BR/>#51. MH 'education&#8217;<BR/>#52. MH 'attitude'<BR/>#53. MH 'cognition'<BR/>#54. MH 'health behavior'<BR/>#55. MH 'decision making'<BR/>#56 OR/#19-#55<BR/>#67 #18 AND #56</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">LILACS (1982 to 15 January 2012) and IMEMR (1984 to 15 January 2012):</HEADING>
<P>#1 congenital toxoplasmosis</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-07-28 13:33:09 +0100" MODIFIED_BY="Heather Maxwell" NO="2">
<TITLE MODIFIED="2015-05-12 09:39:55 +0100" MODIFIED_BY="[Empty name]">Methods to be used in future updates</TITLE>
<APPENDIX_BODY MODIFIED="2015-07-28 13:33:09 +0100" MODIFIED_BY="Heather Maxwell">
<P>The following methods section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Group.</P>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors will independently assess for inclusion all the potential studies identified as a result of the search strategy. We will resolve any disagreement through discussion or, if required, we will consult the third review author.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>We will design a form to extract data. For eligible studies, two review authors will extract the data using the agreed form. We will resolve discrepancies through discussion or, if required, we will consult the third review author. Data will be entered into Review Manager software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>) and checked for accuracy.</P>
<P>When information regarding any of the above was unclear, we plan to contact authors of the original reports to provide further details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two review authors will independently assess risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Any disagreement will be resolved by discussion or by involving a third assessor.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We will assess the method as:</P>
<OL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear risk of bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We will describe for each included study the method used to conceal allocation to interventions prior to assignment and assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We will assess the methods as:</P>
<OL>
<LI>low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We will consider that studies are at low risk of bias if they were blinded, or if we judged that the lack of blinding unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes.</P>
<P>We will assess the methods as:</P>
<OL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We will assess blinding separately for different outcomes or classes of outcomes.</P>
<P>We will assess methods used to blind outcome assessment as:</P>
<OL>
<LI>low, high or unclear risk of bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data are balanced across groups or are related to outcomes. Where sufficient information is reported, or could be supplied by the trial authors, we plan to re-include missing data in the analyses which we undertake.</P>
<P>We will assess methods as:</P>
<OL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomization);</LI>
<LI>unclear risk of bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We will assess the methods as:</P>
<OL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We will describe for each included study any important concerns we had about other possible sources of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We will make explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we plan to assess the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. We will explore the impact of the level of bias through undertaking sensitivity analyses - see Sensitivity analysis.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of treatment effect</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we will present results as summary risk ratio with 95% confidence intervals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We will use the mean difference if outcomes were measured in the same way between trials. We will use the standardised mean difference to combine trials that measured the same outcome, but used different methods.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomized trials</HEADING>
<P>If we identify any cluster-randomized trials, we will include them in the analyses along with individually-randomized trials. We will adjust their sample sizes using the methods described in the <I>Cochrane Handbook for Systematic Reviews of Intervention</I> [Section 16.3.4] using an estimate of the intracluster correlation co-efficient (ICC) derived from similar trial or from a study of a similar population. We will also conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomized trials and individually-randomized trials, we plan to synthesize the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomization unit is considered to be unlikely.</P>
<P>We will also acknowledge heterogeneity in the randomization unit and perform a subgroup analysis to investigate the effects of the randomization unit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other unit of analysis issues</HEADING>
<P>It is unlikely that cross-over designs will be a valid study design for Pregnancy and Childbirth reviews and so, if identified, we will exclude them.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data</HEADING>
<P>For included studies, we will note levels of attrition. If more eligible studies are included, we will explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we will carry out analyses, as far as possible, on an intention-to-treat basis, i.e. we will attempt to include all participants randomized to each group in the analyses. The denominator for each outcome in each trial will be the number randomized minus any participants whose outcomes are known to be missing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity</HEADING>
<P>We will assess statistical heterogeneity in each meta-analysis using the Tau², I² and Chi² statistics. We will regard heterogeneity as substantial if an I² is greater than 30% and either the Tau² is greater than zero, or there is a low P value (less than 0.10) in the Chi² test for heterogeneity. If we identify substantial heterogeneity (above 30%), we plan to explore it by pre-specified subgroup analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases</HEADING>
<P>If there are 10 or more studies in the meta-analysis, we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually. If asymmetry is suggested by a visual assessment, we will perform exploratory analyses to investigate it.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<P>We will carry out statistical analysis using the Review Manager software (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505181226313498151829735742188&amp;format=REVMAN#REF-RevMan-2014">RevMan 2014</A>). We will use fixed-effect meta-analysis for combining data where it is reasonable to assume that studies are estimating the same underlying treatment effect, i.e. where trials are examining the same intervention, and the trials&#8217; populations and methods are judged sufficiently similar.</P>
<P>If there is clinical heterogeneity sufficient to expect that the underlying treatment effects differ between trials, or if substantial statistical heterogeneity is detected, we will use random-effects meta-analysis to produce an overall summary, if an average treatment effect across trials is considered clinically meaningful. The random-effects summary will be treated as the average range of possible treatment effects and we will discuss the clinical implications of treatment effects differing between trials. If the average treatment effect is not clinically meaningful, we will not combine trials. If we use random-effects analyses, the results will be presented as the average treatment effect with 95% confidence intervals, and the estimates of Tau² and I².</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity</HEADING>
<P>If we identify substantial heterogeneity, we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary was meaningful, and if it is, we will use random-effects analysis to produce it.</P>
<P>We plan to carry out all or part of the following subgroup analyses depending on the characteristics of the studies that we will identify:</P>
<OL>
<LI>background risk of infection (studies conducted in area with low incidence rate of congenital toxoplasmosis and studies conducted in areas with high incidence rate of congenital toxoplasmosis);</LI>
<LI>health professionals providing the education (counselors, gynecologists, midwives, etc);</LI>
<LI>information strategy used (printed materials, face-to-face information, class groups, videotapes, etc).</LI>
</OL>
<P>Sugroup analyses will be restricted to primary outcomes.</P>
<P>We will assess subgroup differences by interaction tests available within RevMan (<A HREF="https://archie.cochrane.org/sections/documents/view?version=z1505181226313498151829735742188&amp;format=REVMAN#REF-RevMan-2014">RevMan 2014</A>). We will report the results of subgroup analyses quoting the Chi² statistic and P value, and the interaction test I² value.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>We plan to carry out sensitivity analyses to explore the effect of trial quality assessed by concealment of allocation, high attrition rates, or both, with poor quality studies being excluded from the analyses in order to assess whether this makes any difference to the overall result.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies (4 reports) included. No meta-analysis performed (lack of quantitative comparable data)&lt;/p&gt;" WIDTH="189">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 studies (9 reports) described an educational intervention&lt;/p&gt;" WIDTH="153">
<FLOWCHARTBOX TEXT="&lt;p&gt;35 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="139">
<FLOWCHARTBOX TEXT="&lt;p&gt;926 records screened&lt;/p&gt;" WIDTH="141">
<FLOWCHARTBOX TEXT="&lt;p&gt;925 records identified through database searching&lt;/p&gt;&lt;p&gt;903 from MEDLINE, EMBASE and CINAHL&lt;/p&gt;&lt;p&gt;15 from LILACS&lt;/p&gt;&lt;p&gt;5 from IMEMR&lt;/p&gt;&lt;p&gt;2 from PCG Trials Register&lt;/p&gt;" WIDTH="143"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 additional record identified through searching reference lists of retrieved studies&lt;/p&gt;" WIDTH="188"/>
<OUT TEXT="&lt;p&gt;891 of records excluded on assessment of title and abstract&lt;/p&gt;" WIDTH="159"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26 full-text articles excluded on reading the full text&lt;/p&gt;&lt;p&gt;4 not relevant&lt;/p&gt;&lt;p&gt;11 narrative reviews&lt;/p&gt;&lt;p&gt;5 surveys&lt;/p&gt;&lt;p&gt;6 observational studies&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="148"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3 studies (5 reports) excluded, with reasons&lt;/p&gt;" WIDTH="123"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>